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Background/Aims
DA-9701 (Motilitone) is a new prokinetic agent formulated with Corydalis Tuber and Pharbitis Seed. We assessed the efficacy 
of DA-9701 in symptomatic patients with minimal change esophagitis.
Methods
Patients with minimal change esophagitis presenting with reflux or dyspeptic symptoms were randomly assigned to receive ei-
ther DA-9701 30 mg or placebo t.i.d. (means 3 times a day). After 4 weeks of treatment, the primary efficacy end point de-
termined by changes of the Nepean dyspepsia index questionnaire-Korean version (NDI-K) symptom scores, was analyzed.
Results
Forty-two and 39 patients were assigned to the treatment and control groups, respectively. After 4 weeks, NDI-K symptom  
scores were reduced from 35.4 to 13.5 (P ＜ 0.001) and from 43.0 to 27.7 (P ＜ 0.001) in the treatment and the control 
groups, respectively. However, changes in the symptom scores did not differ between the 2 groups (P = 0.741). Although the 
quality of life scores were significantly improved after 4 weeks in both groups, changes in the quality of life score between 
the baseline value and that at 4 weeks did not differ between the 2 groups. The reflux symptom score was significantly im -
proved in the treatment group compared to the placebo group in patients aged 65 years or older (P = 0.035).
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Conclusions
Although NDI-K symptom scores and quality of life scores were improved after 4 weeks of treatment compared with baseline 
values in patients with minimal change esophagitis, DA-9701 did not improve the symptom scores or quality of life scores 
compared with the placebo.
(J Neurogastroenterol Motil 2014;20:338-346)
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Introduction
Non-erosive reflux disease (NERD) is defined as the pres-
ence of troublesome reflux-associated symptoms and the absence 
of mucosal breaks at endoscopy.1 Endoscopic findings in NERD 
patients can be classified into normal findings and minimal 
change esophagitis.2-6 Minimal change esophagitis is determined 
by a characteristic appearance of the distal end of the esophageal 
mucosa that includes a whitish appearance and/or erythema, 
and/or erosion that is not regarded as a mucosal break.5,6 A pre-
vious study that included 25,536 individuals who underwent up-
per gastrointestinal endoscopic examinations as a health check-up 
showed that minimal change esophagitis was closely related with 
reflux symptoms including heartburn and acid regurgitation.3 
Minimal change esophagitis, however, was also associated with 
dyspeptic symptoms including globus sensation and epigastric 
soreness.3,7 In addition, NERD is very common in the primary 
care setting, and it adversely affects the quality of life.1,8,9 Proton 
pump inhibitors (PPIs), which are used mainly for treating ero-
sive esophagitis, are also commonly used in the treatment of 
NERD.10-12 However, PPIs are less effective in NERD patients 
than in erosive esophagitis patients.13-16 In addition, hiatal hernia 
is less common and gastric atrophy is more severe in patients with 
minimal change esophagitis than in those with erosive esopha-
gitis.13,17 These findings suggest that the characteristics and path-
ophysiology of minimal change esophagitis differ from those of 
erosive esophagitis. As part of an effort to improve the symptoms 
of NERD patients, some studies on prokinetics were conducted.9 
Because prokinetics showed efficacy in patients with erosive 
esophagitis, its effect in patients with NERD was assessed. A 
randomized study, however, demonstrated that addition of mo-
sapride to omeprazole was not more effective than omeprazole 
alone.18 Another study showed that remission of symptoms was 
maintained in fewer than half of patients with NERD who were 
receiving cisapride.19 An effective treatment option for NERD 
patients has not been identified to date.
DA-9701, a newly developed prokinetic agent, has been 
commercially produced under the name Motilitone in the Korea 
since early 2012.20 DA-9701 is formulated with Corydalis Tuber 
and Pharbitis Seed. Both of these plants have been used in 
Oriental traditional medicine for the management of gastro-
intestinal symptoms. Corydalis Tuber, the root of Corydalis yahu-
suo W.T. Wang (Corydalis Tuber, Papaveraceae), has analgesic 
and antiulcer effects.21-23 In addition, Pharbitis Semen, the seed 
of Pharbitis nil Choisy, is believed to have analgesic effects on the 
abdomen.20 DA-9701 has shown affinity for the dopamine (D)2, 
5-hydroxytryptamine (5-HT)4, 5-HT1A and 5-HT1B recep-
tors.24-26 It has antagonistic effects on the D2 receptors and ago-
nistic effects on the 5-HT4, 5-HT1A and 5-HT1B receptors. 
Thus, DA-9701 can improve delayed gastric emptying and may 
be effective as a prokinetic agent.20,27 On the other hand, DA-9701 
increases basal gastric volume and gastric accommodation to a 
meal in animal models.21,26 Whereas other existing prokinetics 
lead mainly to gastric emptying, DA-9701 may have effects on 
both gastric emptying and gastric accommodation. Accordingly, 
DA-9701 is considered as a complex motility agent, which can be 
a solution to resolve the various symptoms of functional dyspep-
sia. In addition, DA-9701 may decrease gastroesophageal reflux 
via these mechanisms. It may help to improve both dyspepsia and 
reflux symptoms in patients with minimal change esophagitis.
Materials and Methods
Design and Participants
The present study was a doubleblind, placebo-controlled 
study with concealed allocation in symptomatic patients with 
minimal change esophagitis conducted at 2 university hospitals. 
Patients with gastrointestinal symptoms including reflux and 
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Table. Baseline Patient Characteristics
　 Treatment group Control group P-value
Patients (n) 42 39
Age (mean ± SD, yr) 48.4 ± 13.9 48.5 ± 13.0 0.978 
Sex (n [%]) 0.643 
Male 13 (33.3) 12 (28.6)
Female 26 (66.7) 30 (71.4)
Body mass index (mean ± SD, kg/m2) 22.4 ± 2.7 23.3 ± 3.3 0.195 
Cigarette smoking (n [%]) > 0.999
Current smoker 4 (10.3) 4 (9.5)
Ex-smoker 2 (5.1) 3 (7.1)
Never smoker 33 (84.6) 35 (83.3)
Alcohol use (n [%]) 14 (35.9) 13 (31.0) 0.637 
NDI-K symptom score (mean ± SD)
Dyspeptic symptom score 30.0 ± 12.8 34.5 ± 14.2 0.138 
Reflux symptom score 5.4 ± 5.0 8.5 ± 6.7 0.024 
Total score 35.4 ± 14.3 43.0 ± 16.0 0.028 
NDI-K quality of life score (mean ± SD)
Interference 77.9 ± 18.1 78.5 ± 17.5 0.868 
Knowledge/control 69.9 ± 17.2 68.5 ± 20.6 0.740 
Eating/drinking 73.2 ± 21.0 76.9 ± 20.3 0.422 
Sleep 78.3 ± 22.1 77.2 ± 20.5 0.829 
Total score 75.1 ± 17.3 75.4 ± 17.7 0.936 
NDI-K, Nepean dyspepsia index questionnaire-Korean version.
dyspepsia symptoms for more than 3 months in a period of 6 
months prior to enrollment who visited the outpatient clinics of 
the participating hospitals were invited to participate in this study. 
Symptoms were confirmed through patient interviews. Patients 
were required to have upper gastrointestinal endoscopy within 1 
month of enrollment and were selected for the study if minimal 
change esophagitis was noted. Minimal change esophagitis was 
defined as the presence of one of the following characteristics at 
the distal end of the esophageal mucosa: whitish change and/or 
erythema, and/or erosion not regarded as mucosal break.5,6 
Patients were also required to be aged 20 years or older, and to be 
outpatients at the relevant center. 
Patients who had apparent causes of gastrointestinal symp-
toms such as gastric ulcer, malignancy, pancreatitis, biliary dis-
ease, irritable bowel syndrome and/or inflammatory bowel disease 
were excluded. Patients with a history of intra-abdominal surgery 
were also excluded. Furthermore, patients who had been treated 
with prokinetics, histamine H2 receptor antagonists, or PPIs 
within 1 month prior to the start of the study were excluded. 
Finally, any patients who were pregnant, lactating and/or who 
were attempting to become pregnant were excluded, as well as pa-
tients who were regarded by the study investigators as not to be 
suitable for participation.
All patients gave their written informed consent to participate 
in the study. The institutional review board of each center ap-
proved this study.
Randomization and Treatment
Randomization was achieved by using a computerized ran-
dom number table with the key code securely stored. Random 
number table was created by one of the investigators (CHP) by 
applying a block randomization method with a block size of 6. 
Patients were randomized to one of the 2 study arms. The pa-
tients in the treatment arm received DA-9701 (Motilitone, 
Dong-A Pharm., Co., Seoul, Korea) 30 mg t.i.d. (means 3 times 
a day) for 4 weeks. The patients in the control arm received place-
bo tablets that were identical to the DA-9701 tablets t.i.d. for 4 
weeks. The following concomitant medications were prohibited: 
prokinetics, PPIs, H2 receptor antagonists, non-steroidal anti-in-
flammatory drugs, corticosteroids and/or anti-cholinergics.
Safety Assessment
Safety profiles were assessed by using review of systems and 
physical examination at screening and at each outpatient clinic 
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visit. Laboratory tests including a complete blood count, bio-
chemistry and electrolytes were performed before and after the 
treatment.
Nepean Dyspepsia Index
The patients’ symptoms and quality of life were assessed by 
using the Nepean dyspepsia index questionnaire-Korean version 
(NDI-K).28 The NDI-K consists of a symptom checklist and a 
disease-specific quality of life measure. The symptom indexes of 
the NDI-K were rated for frequency (scored 0-4), intensity 
(scored 0-5) and bothersomeness (scored 0-4). The higher num-
bers represented the worsening of each symptom. Among the 15 
items of the NDI-K symptom checklist, we used 8 and 2 items 
that represent dyspepsia and reflux, respectively. In addition, 
quality of life scores were obtained by using the NDI-K quality of 
life scale, which consists of 25 items, with a total score ranging 
from 0 to 99. The NDI-K quality of life scale measures the qual-
ity of life in four domains: interference (13 items), knowl-
edge/control (7 items), eating/drinking (3 items) and sleep (2 
items).
Patients’ and Investigators’ Global 
Assessment
After 4 weeks of treatment, patients rated the efficacy of the 
drug by completing a self-reported questionnaire with a 7-point 
Likert scale ranging from “no response” to “complete response.” 
Patients who reported the efficacy of the drug as “no response” or 
“slight response” were classified as non-response group, while 
others that reported the efficacy as higher than “slight response” 
were classified as response group. In addition, investigators as-
sessed whether the patients were improved or not after 4 weeks of 
treatment.
Study Endpoint
The primary endpoint for the study was the changes of 
NDI-K symptom score of 8 dyspeptic and 2 reflux symptoms at 
week 4. In addition, the following secondary endpoints were as-
sessed: NDI-K symptom scores of 2 reflux symptoms and 
changes from baseline, NDI-K quality of life scores and changes 
from baseline, and the patients’ and investigators’ global assess-
ment. As an exploratory data analysis, subgroup analyses for eld-
erly patients aged 65 years or older were performed.
Statistical Methods
For comparison of continuous variables between the 2 groups, 
the t test was used. Paired data including changes in NDI-K 
symptom scores and NDI-K quality of life scores from the base-
line within each group were compared by using the paired t test. 
Categorical variables were analyzed by using the χ2 test and 
Fisher’s exact test. In addition, the differences in NDI-K symp-
tom scores and NDI-K quality of life scores between the treat-
ment and the control groups were adjusted for baseline values by 
using analysis of covariance.
The efficacy of DA-9701 was determined by using the in-
tention-to-treat analysis. The last observation carried forward 
method was used to impute missing values of the efficiency 
endpoints. A value of P ＜ 0.05 was regarded as a significant dif-
ference for comparisons between groups. All statistical proce-
dures were conducted by using the statistical software SPSS for 
Windows (version 18.0; SPSS Inc., Chicago, IL, USA).
Results
Baseline Characteristics
Of 81 patients enrolled in the study between August 2012 
and July 2013, 42 and 39 were assigned to the treatment and con-
trol groups, respectively. Table shows the baseline patient charac-
teristics including baseline NDI-K symptom scores and quality 
of life scores. The mean age was 48.4 and 48.5 years in the treat-
ment and control groups, respectively (P = 0.978). The pro-
portion of male patients was 33.3% and 28.6% in the treatment 
and control groups, respectively (P = 0.643). Body mass index, 
cigarette smoking and alcohol use did not differ between the 2 
groups. Although the NDI-K dyspeptic symptom scores did not 
differ between the 2 groups, the reflux symptom scores were 
higher in the control group than in the treatment group (P = 
0.024). The total symptom scores were also higher in the control 
group than in the treatment group (P = 0.028). The NDI-K 
quality of life scores in 4 domains and the total quality of life 
scores did not differ between the 2 groups.
Effects on the Nepean Dyspepsia Index 
Questionnaire-Korean Version Symptom 
Score
The total scores of NDI-K were significantly improved after 
4 weeks compared with the baseline values in both groups 
(baseline vs. week 4: DA-9701, 35.4 ± 14.3 vs. 13.5 ± 11.1, P 
＜ 0.001; placebo, 43.0 ± 16.0 vs. 27.7 ± 14.4, P ＜ 0.001) 
(Fig. 1). However, DA-9701 did not show a significant change 
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Figure 1. Total scores of the Nepean 
dyspepsia index questionnaire-Korean 
version symptom index including 8 
dyspeptic symptoms and 2 reflux symp-
toms (A) and changes from baseline (B). 
*P ＜ 0.05 compared with score at 
baseline in each group.
Figure 2. Nepean dyspepsia index que-
stionnaire-Korean version symptom scores
of 2 reflux symptoms (A) and changes 
from baseline (B). *P ＜ 0.05 compared 
with score at baseline. 
Figure 3. Nepean dyspepsia index ques-
tionnaire-Korean version quality of life 
scores (A) and changes from baseline 
(B). *P ＜ 0.05 compared with score at 
baseline in each group.
compared with placebo (22.0 ± 13.6 vs. 27.8 ± 14.4, P = 
0.741). Figure 2 shows the NDI-K symptom scores correspond-
ing to 2 reflux symptoms. Along with the results of the total 
NDI-K symptom scores, the NDI-K reflux symptom scores were 
significantly improved after 4 weeks compared with the baseline 
values in both groups. However, changes in the reflux symptom 
scores between the baseline values and those at week 4 did not 
differ between the treatment and control groups (P = 0.573) 
(Fig. 2).
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Figure 4. Percentage of patients who showed a response to the drugs 
according to the patients’ (A) and investigators’ global assessment (B).
Figure 5. Nepean dyspepsia index 
questionnaire-Korean version symptom 
score of 2 reflux symptoms (A) and 
changes from baseline (B) in elderly 
patients. *P ＜ 0.05 compared with score 
at baseline.
Effects on the Nepean Dyspepsia Index 
Questionnaire-Korean Version Quality of Life 
Score
Figure 3 shows the NDI-K quality of life scores and changes 
from baseline. The quality of life scores were significantly im-
proved after 4 weeks in both groups (baseline vs. week 4: 
DA-9701, 75.1 ± 17.3 vs. 86.6 ± 13.6, P ＜ 0.001; placebo, 
75.4 ± 17.7 vs. 86.4 ± 11.6, P ＜ 0.001). The quality of life 
scores for 4 domains (interference, knowledge/control, eat-
ing/drinking and sleep) were significantly improved in both treat-
ment and control groups (data not shown). However, changes in 
the quality of life scores between the baseline values and those at 
week 4 did not differ between the 2 groups (P = 0.877).
Patients’ and Investigators’ Global 
Assessment
Percentages of patients who showed a response to the drugs 
according to the patients’ and the investigators’ global assess-
ments are shown in Figure 4A and 4B, respectively. The percen-
tages of patients whose symptoms were improved after 4 weeks of 
treatment did not differ between the 2 groups (DA-9701 vs. pla-
cebo; patients’ assessment, 76.2% vs. 66.7%, P = 0.342; inves-
tigators’ assessment, 71.4% vs. 66.7%, P = 0.643).
Effects on the Nepean Dyspepsia Index 
Questionnaire-Korean Version Reflux 
Symptom Scores in Elderly Patients
The NDI-K reflux symptom scores in elderly patients are 
shown in Figure 5. The reflux symptom scores were significantly 
improved in the treatment group, but not in the control group 
(baseline vs. week 4: DA-9701, 5.7 ± 4.2 vs. 3.3 ± 2.9, P = 
0.035; placebo, 6.8 ± 6.9 vs. 8.0 ± 5.5, P = 0.411). Changes in 
the reflux symptom scores between the baseline values and those 
at week 4 were more significant in the treatment group than in the 
control group (P = 0.009). In the treatment group, changes in 
the reflux symptom score did not differ between elderly and 
non-elderly patients (P = 0.632).
Adverse Events
Of 42 patients in the treatment group, 1 patient vomited 
once. In addition, 1 patient had mild diarrhea and 1 patient had a 
mild cough in the control group. No other patients showed ad-
verse events.
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Discussion
Although PPI is a mainstay of treatment in patients with 
NERD and in those with erosive esophagitis, whether minimal 
change esophagitis is an early endoscopic finding of erosive 
esophagitis remains controversial.9 A nationwide multicenter 
prospective study conducted in Korea demonstrated that the min-
imal changes were closely related with upper gastrointestinal 
symptoms and showed similar risk factors as those of gastro-
esophageal reflux disease (GERD). Therefore, it was suggested 
that minimal changes were considered as early endoscopic find-
ings of GERD.3 However, another prospective multicenter study 
conducted in Korea showed that most of the endoscopic findings 
indicating minimal changes were not associated with GERD.29 
In addition, patients with NERD have been suggested to be of 
heterogeneous group and different mechanisms may be respon-
sible for their symptoms.9 Some patients experience heartburn 
caused by excess acid reflux, whereas others show esophageal 
chemoreceptor sensitivity to physiological amounts of acid. Ano-
ther subgroup of patients may develop heartburn symptoms as a 
result of esophageal motor dysfunction. Hiatal hernia is less com-
mon and severe gastric atrophy is more frequently observed in pa-
tients with minimal change esophagitis than in those with erosive 
esophagitis.13,17 Moreover, PPIs are less effective in NERD pa-
tients than in those with erosive esophagitis patients.13-16 These 
findings suggest that the pathophysiology of minimal change 
esophagitis may be different from that of erosive esophagitis, and 
indicate that the development of more effective treatment options 
is necessary.
In the present study we assessed the efficacy of DA-9701, a 
newly developed prokinetic agent, in patients with minimal 
change esophagitis. Although DA-9701 improved the NDI-K 
symptom scores and quality of life scores after 4 weeks of treat-
ment, an advantage of DA-9701 over placebo was not demon-
strated. These results may be explained based on the ineffective-
ness of DA-9701 in patients with minimal change esophagitis. 
However, the high placebo response rate in this trial might be an-
other reason for the lack of a significant difference in efficacy be-
tween DA-9701 and the placebo. In our study, both of the pro-
portions of patients who showed a response to the placebo accord-
ing to the patients’ and the investigators’ global assessment were 
66.7%. A previous meta-analysis on GERD showed that the pla-
cebo response rate tended to increase in patients with NERD 
compared to those with erosive esophagitis (placebo response 
rate: NERD vs. erosive esophagitis, 18.31% vs. 11.87%, P = 
0.246).30 Furthermore, the placebo response rates in patients with 
functional dyspepsia were 30-50%.31-33 Because minimal change 
esophagitis patients who had symptoms including dyspepsia were 
included in the study, the placebo response rate was higher in our 
study than in previous studies on GERD. We believe that the 
high placebo response may have masked the differences in the ef-
ficacy of DA-9701 in patients with minimal change esophagitis.
We performed exploratory data analyses by dividing the pa-
tient population into various subgroups. The main purpose of 
this additional analysis was to identify low placebo response 
subgroups. The results showed that elderly patients aged 65 years 
or older had a low placebo response regarding reflux symptoms. 
DA-9701, however, showed similar efficacy on reflux symptoms 
between elderly and non-elderly patients. In addition, DA-9701 
had an advantage on reflux symptoms over placebo in the sub-
group of elderly patients. Despite the possibility of coincidental 
findings, we think that the efficacy of DA-9701 on reflux symp-
toms should be reinvestigated carefully in selected patients who 
do not respond to placebo.
Although this was a randomized, doubleblind, placebo-con-
trolled study, there were several limitations. Firstly, several fac-
tors associated with the severity of symptoms in patients with 
NERD or erosive esophagitis, including hiatal hernia, atrophic 
gastritis, and Helicobacter pylori infection status, were not 
assessed. Although the randomized design of the study should 
minimize selection bias including hidden risk factors, an even 
distribution of all risk factors was not guaranteed. Secondly, we 
could not distinguish the patients with GERD from those with 
functional heartburn because 24-hour esophageal pH monitoring 
was not performed. Although such an exam is not a primary diag-
nostic option prior to treatment in patients with NERD, it would 
help to identify a subgroup of patients who would benefit from 
DA-9701 treatment. Thirdly, although we showed a low placebo 
response rate in elderly patients and an advantage of DA-9701 on 
reflux symptoms over placebo, it has not been proven that elderly 
patients generally have a lower placebo response rate than 
non-elderly patients. One previous study with pooled analysis, 
however, showed that elderly patients had a lower placebo re-
sponse rate for migraine than younger patients.34 Our result, with 
a low placebo rate for reflux symptoms in elderly patients with 
NERD, should be supported by further studies.
Our results showed that DA-9701 did not improve the 
symptom scores nor quality of life scores in comparison with the 
placebo despite an improvement in the NDI-K symptom scores 
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and quality of life scores after 4 weeks of treatment compared 
with baseline values in patients with minimal change esophagitis. 
The effect of DA-9701 on reflux symptoms in elderly patients, 
however, may be meaningful and merit further investigation. 
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